Michael Raymer’s Post

Exciting News! 🌐 Simulations Plus, Inc. has announced the extension of our collaboration with the Translational Toxicology Division at the National Institute of Environmental Health Sciences (NIEHS). 🚀 Cutting-edge computational tools, including ADMET Predictor® and GastroPlus®, are at the forefront of supporting rapid safety assessments of chemicals in animals and humans. 🧪💻 These tools enable in vitro to in vivo extrapolation (IVIVE), providing precise estimates of chemical safety margins and integrating diverse toxicology data for informed decision-making. 📊 We take pride in contributing to the groundbreaking environmental health and safety research activities led by DTT/NIEHS. As in vivo testing becomes more limited, our software plays a crucial role in supporting new approach methodologies (NAMs) to predict outcomes related to chemical reactions in the body. #GastroPlus, our mechanistically based #modelingandsimulation software, and #ADMET Predictor, our AI machine learning platform, are essential in understanding and modeling new molecules' absorption, distribution, metabolism, excretion, and toxicity. 🧬💊 If you'd like to join us on this exciting journey of advancing scientific knowledge and fostering innovation in the pharmaceutical, biotechnology, chemicals, and consumer goods industries, DM me! 🌟 #SimulationsPlus #ComputationalTools #ToxicologyResearch #EnvironmentalHealth Read more: https://lnkd.in/gMakty-h

Interesting read

The Dexalytics Blog is a library of helpful information and tips about using DXA, new university research, measuring and managing body composition, health and performance of athletes, news, and more! Check it out here! https://loom.ly/iyz3GDs

The Dexalytics Blog is a library of helpful information and tips about using DXA, new university research, measuring and managing the body composition, health and performance of athletes, news, and more! Check it out here! https://loom.ly/iyz3GDs

Fascinating Low Valuation on IPA Therapeutics(NASDAQ:IPA $1.26) On March 29, 2022 IPA paid $20 million euros or approximately $22 million USD for BioStrand AI. The euro was trading(1 euro = 1.10 USD) at this time. Since this acquisition BioStrand AI has announced several significant events/successes including, granting of the HYFT Technology Patent by the European Patent Office(EPO), BioStrand solves the Information Integration Dilemma(IID), BioStrand creates a revolutionary approach to biological sequence retrieval, BioStrand introduces an advanced Foundational AI Model utilizing LLM stacking & HYFT Technology, InterSystems & BioStrand AI Collaborate to Unveil Innovative Integration of Vector Search, BioStrand's AI has been learning from IPA's leading, proprietary Antibody Discovery Database(possibly the best in the World)for the last 24 months, and much more. IPA has been working on antibody research for 40+ years. https://lnkd.in/gJHWdgck https://blog.biostrand.ai Yet, the entire current Market Capitalization of IPA(CRO + BioStrand + Talem) is approximately $35 million USD today. IPA's Contract Research Organization(CRO) has had 3 record revenue quarters in a row, is growing at approx. 20%, and Fiscal 2024 Revenue should be around $20 million USD. They deal with 19 of the top 20 pharmas, and have over 600 partners. One could argue that the CRO is worth between $80-$120 million. FairJourney Biologics(an excellent CRO) was just put up for sale for $1 Billion+. Although FJBio has $45 million in projected EBITA, IPA has better numbers regarding projects, libraries generated, partners, species used, and 1/2 the employees. In other words, better data to train the AI models. Wet lab combined with AI will be critical moving forward. I also believe BioStrand AI is undiscovered by most stock market participants. For Information Purposes Only. Please complete your own due diligence. CFP has a position in IPA. Is a short squeeze possible? Sum of the parts(1 + 1 = 11) IPA (ImmunoPrecise Antibodies)BioStrand (a subsidiary of IPA) InterSystems hashtag #ai hashtag #HYFTTechnology hashtag #drugdiscovery hashtag #LENSai hashtag #antibodies hashtag #LLMS hashtag #NLP hashtag #semantics hashtag #pharma hashtag #healthcare hashtag #biotech hashtag #multimodality

The benefit of GLP-1RA semaglutide in preventing the progression of renal events in the FLOW trial. DSMB stops the trial early for efficacy! https://lnkd.in/dB4t3jZx

Our latest article

In conclusion of 4Q23 earnings, President and CEO Jody Staggs highlights SWK Holdings Corporation’s achievements in the fourth quarter of 2023, including its balance sheet and closed transactions.   Jody’s remarks can be found below.   If you would like more information regarding 4Q23 earnings, please click the link below.   #SWKH #Q4 #Earnings #Biotechnology #LifeScience 

It is amazing to see the commercial appeal of Novo's "weight loss" (+heart issues) drugs. Novo Nordisk increased revenue and profit guidance once again 😮 . The optimism around the share price consolidates the company as the largest market cap in Europe (>$450bn). Consensus still has a c.10% upward adjustment to make to revenues to catch up with the new guidance for the year (c.35% vs c.30% previously). At 20-25x 2025 earnings the company does not screen as rich, looking at historical levels and, considering the demographic trends, Novo is likely to be a perma-winner. Let's now wait for the full 9M23 numbers on 2-Nov. #novo #novonordisk #pharma #diabetes #obesity #ozempic #wegovy https://lnkd.in/ehqJJq8f

A useful insights from BOYDS